InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the “Global Antibody and Recombinant Protein CDMO Market – (By Type (Antibody CDMO, Recombinant Protein CDMO), By Application (Pharmaceutical Company, Biotechnology Company, Generic Company)), Trends, Industry Competition Analysis, Revenue and Forecast To 2031.”
According to the latest research by InsightAce Analytic, the Global Antibody and Recombinant Protein CDMO Market is valued at US$ 16.2 Bn in 2023, and it is expected to reach US$ 36.1 Bn by 2031, with a CAGR of 10.8% during the forecast period of 2024-2031.
Get Free Access to Demo Report, Excel Pivot and ToC : https://www.insightaceanalytic.com/request-sample/2664
An Antibody and Recombinant Protein CDMO (Contract Development and Manufacturing Organization) is a specialized entity that offers services for the development and manufacturing of antibodies and recombinant proteins on behalf of other organizations, particularly in the pharmaceutical and biotechnology sectors. Cell line development, process optimization, biologics production, and scale-up are among the services provided by these CDMOs. The pharmaceutical industry’s growing need for biologics, along with developments in biotechnology and research, is what’s driving this increase. Antibody and recombinant protein development and manufacturing activities are increasingly being outsourced to specialist CDMOs in an effort to cut costs and increase efficiency, which is predicted to drive further market expansion.
List of Prominent Players in the Antibody and Recombinant Protein CDMO Market:
- Batavia Biosciences
- Grifols
- Biovian Oy
- Catalent
- Bioinnobio
- Thousand Oaks Biopharmaceuticals
- Goodwin Biotechnology
- Cerbios-Pharma SA
- HALIX
- Merck
- Hangzhou Hs-biopharm
- Wuxibiologics
- Cerbios-Pharma SA
- Genscriptprobio
- Vetter
- Etinpro (Beijing) Co
- Boehringer Ingelheim BioXcellence
- Eurogentec
- HJB
- Bibo Pharma
- MabPlex International
- Lonza
- 3SBio Inc
- Porton
Expert Knowledge, Just a Click Away: https://calendly.com/insightaceanalytic/30min?month=2024-02
Market Dynamics:
Drivers-
The need for antibody and recombinant protein CDMO services is being driven by the rising incidence of chronic diseases and the expanding use of biologics for disease therapy. Additionally, continuing biotechnology developments like protein engineering and recombinant DNA technologies are propelling the creation of innovative biologics and raising the need for CDMO services. The market for recombinant proteins and antibodies is predicted to increase rapidly due to favourable regulatory rules and incentives supporting the development and production of biologics.
Challenges:
The creation and production of biologics, such as recombinant proteins and antibodies, come at a high cost, which hinders the expansion of the market. The operational problems faced by CDMO providers are increased by the need to comply with complicated regulatory standards for biologics production and quality control. Additionally, the market for antibody and recombinant protein CDMOs is constrained by the limited capacity of biologics manufacturing and the challenges of process scaling.
Regional Trends:
The North American antibody and recombinant protein CDMO market is anticipated to report a prominent market share in terms of revenue. The United States and Canada are the primary countries in North America driving market expansion. These nations’ robust pharmaceutical industries and research capacities have created a sizable increase in the market. Additionally, important factors supporting this industry’s growth include the presence of major pharmaceutical & biotechnology companies along with a well-functioning healthcare system. The region is witnessing a swell in investments in healthcare infrastructure, coinciding with the growing need for personalized medicine. The market is expanding because of the region’s growing focus on research and development projects.
Empower Your Decision-Making with 180 Pages Full Report @ https://www.insightaceanalytic.com/enquiry-before-buying/2664
Segmentation of Antibody and Recombinant Protein CDMO Market-
By Type-
- Antibody CDMO
- Recombinant Protein CDMO
By Application-
- Pharmaceutical Company
- Biotechnology Company
- Generic Company
By Region-
North America-
- The US
- Canada
- Mexico
Europe-
- Germany
- The UK
- France
- Italy
- Spain
- Rest of Europe
Asia-Pacific-
- China
- Japan
- India
- South Korea
- South East Asia
- Rest of Asia Pacific
Latin America-
- Brazil
- Argentina
- Rest of Latin America
Middle East & Africa-
- GCC Countries
- South Africa
- Rest of the Middle East and Africa
Unlock Your GTM Strategy: https://www.insightaceanalytic.com/customisation/2664
About Us:
InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.
Media Contact
Company Name: InsightAce Analytic Pvt. Ltd
Contact Person: Diana D’Souza
Email: Send Email
Country: United States
Website: https://www.insightaceanalytic.com/
Press Release Distributed by ABNewswire.com
To view the original version on ABNewswire visit: Antibody and Recombinant Protein CDMO Market: Key Trends and Growth Forecasts